TY  - GEN
AU  - Witzel,Isabell
AU  - Loibl,Sibylle
AU  - von Minckwitz,Gunter
AU  - Mundhenke,Christoph
AU  - Huober,Jens
AU  - Hanusch,Claus
AU  - Henschen,Stephan
AU  - Hauschild,Maik
AU  - Lantzsch,Tilmann
AU  - Tesch,Hans
AU  - Latos,Kunibert
AU  - Just,Marianne
AU  - Hilfrich,Jörn
AU  - Barinoff,Jana
AU  - Eulenburg,Christine Zu
AU  - Roller,Marc
AU  - Untch,Michael
AU  - Müller,Volkmar
TI  - Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
SN  - 1573-7217
PY  - 2010///1208
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Biomarkers, Tumor
KW  - blood
KW  - Breast Neoplasms
KW  - Chemotherapy, Adjuvant
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Female
KW  - Germany
KW  - Humans
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Odds Ratio
KW  - Receptor, ErbB-2
KW  - antagonists & inhibitors
KW  - Time Factors
KW  - Trastuzumab
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10549-010-1030-9
ER  -